Hsbc Holdings PLC Adc Therapeutics Sa Call Options Transaction History
Hsbc Holdings PLC
- $176 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADCT
# of Institutions
107Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...